HMG and LGD-4033 Interaction: Monitor | Peptide Database

Join others researching Meldonium — share findings, ask questions, and learn from real experiences Meldonium (marketed as Mildronate) is a cardioprotective and anti-ischemic drug developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. It is approved and widely prescribed in Latvia, Lithuania, Russia, and several other post-Soviet states for the treatment of coronary artery disease, heart failure, and cerebrovascular conditions. Meldonium has never been approved by the FDA or EMA, and it remains unavailable through conventional pharmaceutical channels in the United States and most of Western Europe. The drug gained worldwide notoriety in March 2016 when tennis star Maria Sharapova announced she had tested positive for meldonium after the World Anti-Doping Agency (WADA) added it to the Prohibited List effective January 1, 2016. Her positive test was far from isolated -- WADA reported that meldonium was the most common substance detected in doping control samples in early 2016, with hundreds of athletes across multiple sports testing positive, predominantly from Eastern European and Central Asian countries. This widespread use reflected meldonium's longstanding popularity among athletes in those regions, where it was both legally available by prescription and culturally accepted as a general-purpose cardioprotective and performance-enhancing agent. In the performance enhancement community, meldonium has attracted particular interest among anabolic steroid users seeking cardiac protection during cycles, given the well-documented cardiotoxic effects of supraphysiological androgen use including left ventricular hypertrophy, impaired diastolic function, and accelerated atherosclerosis. Meldonium exerts its primary pharmacological effect by inhibiting gamma-butyrobetaine hydroxylase (BBOX), the enzyme responsible for the final step in the biosynthesis of L-carnitine from gamma-butyrobetaine (GBB). By competitively blocking this enzyme, meldonium reduces endogenous carnitine production, which in turn lowers intracellular carnitine concentrations over time. Since carnitine is essential for the transport of long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, reduced carnitine levels impair fatty acid beta-oxidation. This forces cells -- particularly cardiomyocytes and skeletal muscle cells -- to shift their metabolic fuel preference from fatty acid oxidation toward glucose oxidation. This metabolic shift is the cornerstone of meldonium's cardioprotective mechanism. Under ischemic conditions (reduced blood flow), fatty acid oxidation becomes metabolically inefficient and even harmful: incomplete fatty acid oxidation generates toxic intermediates (long-chain acylcarnitines and acyl-CoA species) that damage cell membranes and impair mitochondrial function. Glucose oxidation, by contrast, requires less oxygen per molecule of ATP produced and does not generate these toxic intermediates. By forcing the heart to rely more on glucose, meldonium effectively optimizes energy production under oxygen-limited conditions and reduces the accumulation of cardiotoxic lipid metabolites. Additionally, the accumulation of GBB that results from BBOX inhibition has been shown to stimulate nitric oxide (NO) production via an ester-mediated mechanism, promoting vasodilation, improving endothelial function, and reducing peripheral vascular resistance. Meldonium also upregulates the expression of glucose transporter proteins (GLUT-1 and GLUT-4) and activates components of the Akt-dependent cardioprotective signaling pathway, further enhancing myocardial resistance to ischemic injury.

First-line pharmacotherapy for type 2 diabetes per ADA/EASD guidelines. Reduces HbA1c by 1.0-1.5% as monotherapy. Proven cardiovascular mortality reduction in the UKPDS trial. Can be used alone or in combination with other antidiabetic agents. Delays or prevents progression from prediabetes to type 2 diabetes. The Diabetes Prevention Program (DPP) showed a 31% reduction in diabetes incidence with metformin compared to placebo over 2.8 years. Particularly effective in younger, more obese individuals. Improves multiple components of metabolic syndrome including fasting glucose, insulin resistance, and visceral adiposity. Often used off-label in non-diabetic individuals with metabolic syndrome who have failed lifestyle interventions. Improves insulin resistance, reduces androgen levels, and may restore ovulatory function in women with PCOS. Used as adjunctive therapy alongside lifestyle modifications. Effectiveness varies and is most pronounced in women with significant insulin resistance. Observational studies suggest diabetic patients on metformin may have lower all-cause mortality than non-diabetic controls. The TAME trial is the first FDA-approved clinical trial to specifically target aging as an indication. Proposed mechanisms include AMPK activation, mTOR inhibition, reduced inflammation, and enhanced autophagy. Multiple observational studies and meta-analyses suggest 20-40% reduced incidence of several cancers (colorectal, breast, prostate, pancreatic) in metformin users versus other antidiabetic therapies. Proposed mechanisms include AMPK-mediated mTOR inhibition and reduced circulating insulin/IGF-1 levels. Prospective clinical trials are ongoing. The UKPDS demonstrated a 39% reduction in myocardial infarction risk in overweight diabetic patients treated with metformin. Mechanisms include improved endothelial function, reduced oxidative stress, and anti-inflammatory effects independent of glucose lowering. Metformin is weight-neutral to mildly weight-reducing, unlike many other diabetes medications. Typical weight loss is 1-3 kg over 6-12 months. May reduce visceral fat preferentially. Often prescribed off-label for weight management in non-diabetic individuals with insulin resistance.